ESMO 2024 | The future of antibody-drug conjugates in urothelial carcinoma
Jonathan Rosenberg
• 16 Sep 2024
Jonathan Rosenberg, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on unanswered questions in the field of antibody-drug conjugates (ADCs) for urothelial carcinoma. Future ADCs under development need to have fewer toxicities, such as dermatologic immune-related adverse events and mucositis in the case of FGFR3-targeting ADCs. More second-line options are additionally needed, and more research is needed on the role of nectin-4 ADCs in the refractory setting. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
